Shimotori T, Sakuragawa N
Department of Clinical Laboratory Medicine, Faculty of Medicine, Toyama Medical and Pharmaceutical University, Japan.
Semin Thromb Hemost. 1990 Oct;16 Suppl:71-6.
The accelerating effects of an UF heparin (Novo) and two LMW heparins (Fragmin and PK 10169) on AT III and HC II were investigated in a purified system. The effects of these heparins on APTTs were examined using human plasma. Fractionation of these heparins by affinity column chromatography yielded the following results: UF heparin was separated into two distinct fractions, LA and HA for AT III. Both LMW heparins were separated into three fractions: NA, LA, and HA for AT III. The accelerating effects of these fractions on both antithrombin and anti-Factor Xa activity of AT III were dependent on the strength of their affinity to AT III. The accelerating effects of these fractions on the antithrombin activity of HC II was independent of the strength of their affinity for AT III. LA had a much stronger anticoagulant activity of HC II toward thrombin than did HA. It is concluded that LA for AT III is necessary to show HC II activity.
在一个纯化系统中研究了普通肝素(诺和诺德公司生产)和两种低分子肝素(法安明和PK 10169)对抗凝血酶III(AT III)和肝素辅因子II(HC II)的加速作用。使用人血浆检测了这些肝素对活化部分凝血活酶时间(APTT)的影响。通过亲和柱色谱法对这些肝素进行分级分离得到以下结果:普通肝素被分离成两个不同的级分,即针对AT III的LA和HA。两种低分子肝素均被分离成三个级分:针对AT III的NA、LA和HA。这些级分对AT III的抗凝血酶和抗Xa因子活性的加速作用取决于它们与AT III亲和力的强度。这些级分对HC II抗凝血酶活性的加速作用与它们对AT III亲和力的强度无关。LA对HC II针对凝血酶的抗凝活性比HA强得多。得出的结论是,针对AT III的LA对于显示HC II活性是必要的。